youtube_live
Q3 2026 earnings • released • EPS beat +31.53% • Revenue beat +6.56%
See resultschevron_right
BIIB:NASDAQ
Biogen Inc
$253.18
arrow_upward
+3.74%(+9.13) 1D
Oct 29, 11:23:04 AM GMT-4 · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for BIIB...
Open
$250.15
High
$255.55
Low
$246.48
Mkt. cap
37.41B
Avg. vol.
1.33M
Volume
252.86K
P/E ratio
44.84
52-wk high
$258.63
52-wk low
$138.00
EPS
$5.65
Beta
0.09
Shares outstanding
147.75M
No. of employees
8K
Open
$250.15
High
$255.55
Low
$246.48
Mkt. cap
37.41B
Avg. vol.
1.33M
Volume
252.86K
P/E ratio
44.84
52-wk high
$258.63
52-wk low
$138.00
EPS
$5.65
Beta
0.09
Shares outstanding
147.75M
No. of employees
8K
News stories
From web sources and news partners
Investing.com
·
2 hours ago
Argus upgrades Biogen stock rating on rare disease strength
Yahoo Finance
·
2 hours ago
Biogen Inc. (BIIB) Stock Forecasts
Benzinga
·
3 hours ago
Microsoft To Rally More Than 22%? Here Are 10 Top Analyst Forecasts For Thursday
Benzinga
·
3 hours ago
These Analysts Increase Their Forecasts On Biogen After Upbeat Q3 Results
Profile
Biogen Inc. is an American multinational biotechnology company based in Cambridge, Massachusetts, United States specializing in the treatment of neurological diseases. The company's primary products are dimethyl fumarate, diroximel fumarate, interferon beta-1a, peginterferon beta-1a, and natalizumab, all for the treatment of multiple sclerosis; nusinersen for the treatment of spinal muscular atrophy; omaveloxolone for the treatment of Friedreich's ataxia; tofersen for the treatment of ALS; and dimethyl fumarate for the treatment of severe plaque psoriasis. The company also produces 5 biosimilars and has collaborations with Genentech for several drugs.
The company is ranked 424th on the Fortune 500 and 845th on the Forbes Global 2000. Wikipedia
About Biogen Inc
CEOChris Viehbacher
Employees7.5K
Founded1978
HeadquartersCambridge, Massachusetts, United States
SectorBiotechnology
Websitebiogen.com